{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,9]],"date-time":"2026-10-09T23:26:50Z","timestamp":1791588410103,"version":"4.3.4"},"reference-count":47,"publisher":"Georg Thieme Verlag KG","issue":"01","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Semin Thromb Hemost"],"published-print":{"date-parts":[[2025,2]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>The American Society of Hematology\u2013International Society on Thrombosis and Haemostasis\u2013National Hemophilia Foundation\u2013World Federation of Hemophilia 2021 International Guidelines (IGL) on von Willebrand disease (VWD) have pointed out many challenges, mainly in the diagnostic approach of VWD patients. To determine the impact of these IGL on the current clinical and laboratory diagnosis of Italian VWD patients, we have recently conducted a survey among 43 centers affiliated with the Italian Association of Hemophilia Centers (AICE). Directors and colleagues responsible for the management of VWD patients were invited to report in a detailed questionnaire how IGL recommendations about the assessment of the specific activities of von Willebrand Factor (VWF) could be applied at their local sites. Results from such a survey showed that bleeding assessment tools, VWF antigen, and factor VIII procoagulant are currently in use in all centers. The automated assays for platelet-dependent VWF activity with or without ristocetin described in IGL have been used since 2021 in 37\/43 (86%) centers. Among other laboratory tests, VWF collagen binding, ristocetin-induced platelet agglutination, multimeric analysis, VWF propeptide, VWF:FVIII binding assay were available in 49, 63, 26, 7, and 28% of AICE, respectively. Analyses of VWF gene defects are available only at 3\/43 (7%) centers. Desmopressin (DDAVP) infusion trials at diagnosis, with measurements of VWF activities at 1 and 4\u2009hours post-DDAVP, is currently performed at 38\/43 (88%) centers. Based on this information, a simplified clinical diagnosis using a few automated tests before and after DDAVP has been proposed. Such a diagnostic approach will be validated prospectively in a large cohort of Italian VWD patients.<\/jats:p>","DOI":"10.1055\/s-0044-1787841","type":"journal-article","created":{"date-parts":[[2024,7,1]],"date-time":"2024-07-01T23:15:57Z","timestamp":1719875757000},"page":"081-090","source":"Crossref","is-referenced-by-count":7,"title":["Current Diagnosis of von Willebrand Disease in Italy: 3 Years Following the Release of the International Guidelines"],"prefix":"10.1055","volume":"51","author":[{"given":"Augusto B.","family":"Federici","sequence":"additional","affiliation":[{"name":"Hematology and Transfusion Medicine, School of Medicine of the University of Milan, L. Sacco University Hospital, Milan, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"194","published-online":{"date-parts":[[2024,7,1]]},"reference":[{"issue":"21","key":"ref1","doi-asserted-by":"crossref","first-page":"2067","DOI":"10.1056\/NEJMra1601561","article-title":"Von Willebrand's Disease","volume":"375","author":"F WG Leebeek","year":"2016","journal-title":"N Engl J Med"},{"issue":"02","key":"ref2","doi-asserted-by":"crossref","first-page":"454","DOI":"10.1182\/blood.V69.2.454.454","article-title":"Epidemiological investigation of the prevalence of von Willebrand's disease","volume":"69","author":"F Rodeghiero","year":"1987","journal-title":"Blood"},{"issue":"06","key":"ref3","doi-asserted-by":"crossref","first-page":"893","DOI":"10.1016\/S0022-3476(05)80384-1","article-title":"Prevalence of von Willebrand disease in children: a multiethnic study","volume":"123","author":"E J Werner","year":"1993","journal-title":"J Pediatr"},{"issue":"05","key":"ref4","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1046\/j.1365-2516.2002.00672.x","article-title":"Guidelines for the diagnosis and management of von Willebrand disease in Italy","volume":"8","author":"A B Federici","year":"2002","journal-title":"Haemophilia"},{"issue":"03","key":"ref5","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1111\/j.1365-2516.2004.00894.x","article-title":"The diagnosis of von Willebrand disease: a guideline from the UK Haemophilia Centre Doctors' Organization","volume":"10","author":"M Laffan","year":"2004","journal-title":"Haemophilia"},{"issue":"03","key":"ref6","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1111\/j.1365-2516.2004.00886.x","article-title":"Management of von Willebrand disease: a guideline from the UK Haemophilia Centre Doctors' Organization","volume":"10","author":"K J Pasi","year":"2004","journal-title":"Haemophilia"},{"issue":"02","key":"ref7","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1111\/j.1365-2516.2007.01643.x","article-title":"von Willebrand disease (VWD): evidence-based diagnosis and management guidelines, the National Heart, Lung, and Blood Institute (NHLBI) Expert Panel report (USA)","volume":"14","author":"W L Nichols","year":"2008","journal-title":"Haemophilia"},{"issue":"05","key":"ref8","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1055\/s-0031-1281037","article-title":"Management of inherited von Willebrand disease in Italy: results from the retrospective study on 1234 patients","volume":"37","author":"A B Federici","year":"2011","journal-title":"Semin Thromb Hemost"},{"issue":"26","key":"ref9","doi-asserted-by":"crossref","first-page":"4037","DOI":"10.1182\/blood-2014-02-557264","article-title":"The bleeding score predicts clinical outcomes and replacement therapy in adults with von Willebrand disease","volume":"123","author":"A B Federici","year":"2014","journal-title":"Blood"},{"issue":"14","key":"ref10","first-page":"1","article-title":"Associazione Italiana Centri Emofilia (AICE), Giampaolo A. Registro Nazionale delle Coagulopatie Congenite","volume":"20","author":"F Abbonizio","year":"2018","journal-title":"Rapporto"},{"issue":"04","key":"ref11","doi-asserted-by":"crossref","first-page":"1104","DOI":"10.1111\/hae.14804","article-title":"Von Willebrand disease: gaining a global perspective","volume":"29","author":"J M O'Sullivan","year":"2023","journal-title":"Haemophilia"},{"key":"ref12","doi-asserted-by":"crossref","first-page":"101018","DOI":"10.1016\/j.blre.2022.101018","article-title":"A need to increase von Willebrand disease awareness: vwdtest.com\u2014a global initiative to help address this gap","volume":"58","author":"F F Corrales-Medina","year":"2023","journal-title":"Blood Rev"},{"issue":"01","key":"ref13","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1182\/bloodadvances.2020003264","article-title":"ASH ISTH NHF WFH 2021 guidelines on the management of von Willebrand disease","volume":"5","author":"N T Connell","year":"2021","journal-title":"Blood Adv"},{"issue":"12","key":"ref14","doi-asserted-by":"crossref","first-page":"2619","DOI":"10.1111\/j.1538-7836.2005.01663.x","article-title":"The discriminant power of bleeding history for the diagnosis of type 1 von Willebrand disease: an international, multicenter study","volume":"3","author":"F Rodeghiero","year":"2005","journal-title":"J Thromb Haemost"},{"issue":"10","key":"ref15","doi-asserted-by":"crossref","first-page":"2164","DOI":"10.1111\/j.1538-7836.2006.02070.x","article-title":"Hemorrhagic symptoms and bleeding risk in obligatory carriers of type 3 von Willebrand disease: an international, multicenter study","volume":"4","author":"G Castaman","year":"2006","journal-title":"J Thromb Haemost"},{"issue":"04","key":"ref16","doi-asserted-by":"crossref","first-page":"766","DOI":"10.1111\/j.1538-7836.2006.01847.x","article-title":"A quantitative analysis of bleeding symptoms in type 1 von Willebrand disease: results from a multicenter European study (MCMDM-1 VWD)","volume":"4","author":"A Tosetto","year":"2006","journal-title":"J Thromb Haemost"},{"issue":"01","key":"ref17","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1182\/blood-2006-05-020784","article-title":"Phenotype and genotype of a cohort of families historically diagnosed with type 1 von Willebrand disease in the European study, molecular and clinical markers for the diagnosis and management of type 1 von Willebrand disease (MCMDM-1VWD)","volume":"109","author":"A Goodeve","year":"2007","journal-title":"Blood"},{"issue":"01","key":"ref18","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1182\/blood-2006-05-021105","article-title":"The mutational spectrum of type 1 von Willebrand disease: results from a Canadian cohort study","volume":"109","author":"P D James","year":"2007","journal-title":"Blood"},{"issue":"03","key":"ref19","doi-asserted-by":"crossref","first-page":"526","DOI":"10.1182\/blood-2008-04-152280","article-title":"Clinical and molecular predictors of thrombocytopenia and risk of bleeding in patients with von Willebrand disease type 2B: a cohort study of 67 patients","volume":"113","author":"A B Federici","year":"2009","journal-title":"Blood"},{"issue":"04","key":"ref20","doi-asserted-by":"crossref","first-page":"647","DOI":"10.1160\/TH10-11-0697","article-title":"Bleeding tendency and efficacy of anti-haemorrhagic treatments in patients with type 1 von Willebrand disease and increased von Willebrand factor clearance","volume":"105","author":"G Castaman","year":"2011","journal-title":"Thromb Haemost"},{"issue":"04","key":"ref21","doi-asserted-by":"crossref","first-page":"632","DOI":"10.1111\/j.1538-7836.2012.04661.x","article-title":"Different bleeding risk in type 2A and 2M von Willebrand disease: a 2-year prospective study in 107 patients","volume":"10","author":"G Castaman","year":"2012","journal-title":"J Thromb Haemost"},{"issue":"08","key":"ref22","doi-asserted-by":"crossref","first-page":"1418","DOI":"10.1111\/j.1538-7836.2009.03499.x","article-title":"Evaluation of the diagnostic utility for von Willebrand disease of a pediatric bleeding questionnaire","volume":"7","author":"M Bowman","year":"2009","journal-title":"J Thromb Haemost"},{"issue":"05","key":"ref23","doi-asserted-by":"crossref","first-page":"950","DOI":"10.1111\/j.1538-7836.2010.03796.x","article-title":"Quantitation of bleeding symptoms in children with von Willebrand disease: use of a standardized pediatric bleeding questionnaire","volume":"8","author":"T T Biss","year":"2010","journal-title":"J Thromb Haemost"},{"issue":"09","key":"ref24","doi-asserted-by":"crossref","first-page":"2063","DOI":"10.1111\/j.1538-7836.2010.03975.x","article-title":"ISTH\/SSC bleeding assessment tool: a standardized questionnaire and a proposal for a new bleeding score for inherited bleeding disorders","volume":"8","author":"F Rodeghiero","year":"2010","journal-title":"J Thromb Haemost"},{"issue":"01","key":"ref25","first-page":"55","article-title":"Von Willebrand factor: looking back and looking forward","volume":"98","author":"Z M Ruggeri","year":"2007","journal-title":"Thromb Haemost"},{"issue":"07","key":"ref26","doi-asserted-by":"crossref","first-page":"1345","DOI":"10.1111\/jth.12964","article-title":"Platelet-dependent von Willebrand factor activity. Nomenclature and methodology: communication from the SSC of the ISTH","volume":"13","author":"I Bod\u00f3","year":"2015","journal-title":"J Thromb Haemost"},{"issue":"S 01","key":"ref27","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1111\/ijlh.12540","article-title":"Current and emerging approaches for assessing von Willebrand disease in 2016","volume":"38","author":"A B Federici","year":"2016","journal-title":"Int J Lab Hematol"},{"issue":"05","key":"ref28","doi-asserted-by":"crossref","first-page":"102143","DOI":"10.1016\/j.rpth.2023.102143","article-title":"Laboratory diagnosis of von Willebrand disease in the age of the new guidelines: considerations based on geography and resources","volume":"7","author":"E J Favaloro","year":"2023","journal-title":"Res Pract Thromb Haemost"},{"issue":"06","key":"ref29","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1097\/00001721-200408000-00011","article-title":"A rapid assay for ristocetin cofactor activity using an automated coagulometer (ACL 9000)","volume":"15","author":"A Lattuada","year":"2004","journal-title":"Blood Coagul Fibrinolysis"},{"issue":"06","key":"ref30","doi-asserted-by":"crossref","first-page":"920","DOI":"10.1111\/hae.12203","article-title":"Comparison of a new chemiluminescent immunoassay for von Willebrand factor activity with the ristocetin cofactor-induced platelet agglutination method","volume":"19","author":"N Cabrera","year":"2013","journal-title":"Haemophilia"},{"issue":"02","key":"ref31","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1111\/hae.12064","article-title":"A comparative evaluation of a new automated assay for von Willebrand factor activity","volume":"19","author":"A S Lawrie","year":"2013","journal-title":"Haemophilia"},{"issue":"01","key":"ref32","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1111\/hae.12264","article-title":"A two-centre comparative evaluation of new automated assays for von Willebrand factor ristocetin cofactor activity and antigen","volume":"20","author":"F Stufano","year":"2014","journal-title":"Haemophilia"},{"key":"ref33","first-page":"P07-3","article-title":"Evaluation of a new VWF activity assay based on GPIba in the absence of ristocetin","volume":"30","author":"J Patzke","year":"2010","journal-title":"Haemostesiologie"},{"key":"ref34","doi-asserted-by":"crossref","first-page":"e67","DOI":"10.1182\/blood-2010-08-299016","article-title":"Gain-of-function GPIb ELISA assay for the molecular and clinical biology of VWD","volume":"117","author":"V H Flood","year":"2011","journal-title":"Blood"},{"issue":"01","key":"ref35","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1055\/s-0037-1613768","article-title":"Collagen binding assay for von Willebrand factor (VWF:CBA): detection of von Willebrands Disease (VWD), and discrimination of VWD subtypes, depends on collagen source","volume":"83","author":"E J Favaloro","year":"2000","journal-title":"Thromb Haemost"},{"issue":"06","key":"ref36","first-page":"1127","article-title":"Ristocetin cofactor and collagen binding activities normalized to antigen levels for a rapid diagnosis of type 2 von Willebrand disease\u2014single center comparison of four different assays","volume":"84","author":"A B Federici","year":"2000","journal-title":"Thromb Haemost"},{"issue":"04","key":"ref37","doi-asserted-by":"crossref","first-page":"684","DOI":"10.1373\/clinchem.2012.199000","article-title":"Collagen binding provides a sensitive screen for variant von Willebrand disease","volume":"59","author":"V H Flood","year":"2013","journal-title":"Clin Chem"},{"issue":"10","key":"ref38","doi-asserted-by":"crossref","first-page":"4979","DOI":"10.1182\/blood-2007-09-110940","article-title":"Identification of type 1 von Willebrand disease patients with reduced von Willebrand factor survival by assay of the VWF propeptide in the European study: molecular and clinical markers for the diagnosis and management of type 1 VWD (MCMDM-1VWD)","volume":"111","author":"S L Haberichter","year":"2008","journal-title":"Blood"},{"issue":"12","key":"ref39","doi-asserted-by":"crossref","first-page":"2336","DOI":"10.1182\/blood-2012-09-455089","article-title":"VWF propeptide and ratios between VWF, VWF propeptide, and FVIII in the characterization of type 1 von Willebrand disease","volume":"121","author":"J Eikenboom","year":"2013","journal-title":"Blood"},{"issue":"03","key":"ref40","first-page":"495","article-title":"Quantitative analysis of von Willebrand factor and its propeptide in plasma in acquired von Willebrand syndrome","volume":"80","author":"P J van Genderen","year":"1998","journal-title":"Thromb Haemost"},{"issue":"06","key":"ref41","doi-asserted-by":"crossref","first-page":"2032","DOI":"10.1182\/blood-2003-06-2072","article-title":"Biologic response to desmopressin in patients with severe type 1 and type 2 von Willebrand disease: results of a multicenter European study","volume":"103","author":"A B Federici","year":"2004","journal-title":"Blood"},{"issue":"07","key":"ref42","doi-asserted-by":"crossref","first-page":"3531","DOI":"10.1182\/blood-2007-08-109231","article-title":"Response to desmopressin is influenced by the genotype and phenotype in type 1 von Willebrand disease (VWD): results from the European Study MCMDM-1VWD","volume":"111","author":"G Castaman","year":"2008","journal-title":"Blood"},{"issue":"04","key":"ref43","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1111\/bjh.13064","article-title":"The diagnosis and management of von Willebrand disease: a United Kingdom Haemophilia Centre Doctors Organization guideline approved by the British Committee for Standards in Haematology","volume":"167","author":"M A Laffan","year":"2014","journal-title":"Br J Haematol"},{"key":"ref44","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1016\/j.thromres.2016.02.029","article-title":"Towards a more automatic and rapid laboratory diagnosis of von Willebrand disease","volume":"141","author":"A B Federici","year":"2016","journal-title":"Thromb Res"},{"key":"ref45","doi-asserted-by":"crossref","first-page":"1043","DOI":"10.1111\/j.1538-7836.2012.04729.x","article-title":"Differential sensitivity of von Willebrand factor activity assays to large and small VWF molecular weight forms: a cross-laboratory study comparing ristocetin cofactor, collagen binding and monoclonal antibody-based assays","volume":"10","author":"E J Favaloro","year":"2012","journal-title":"J Thromb Haemost"},{"issue":"01","key":"ref46","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1111\/hae.14204","article-title":"How we diagnose 2M von Willebrand disease (VWD): use of a strategic algorithmic approach to distinguish 2M VWD from other VWD types","volume":"27","author":"E J Favaloro","year":"2021","journal-title":"Haemophilia"},{"issue":"02","key":"ref47","doi-asserted-by":"crossref","first-page":"416","DOI":"10.1182\/bloodadvances.2021005946","article-title":"Commentary on the ASH ISTH NHF WFH 2021 guidelines on the diagnosis of VWD: reflections based on recent contemporary test data","volume":"6","author":"E J Favaloro","year":"2022","journal-title":"Blood Adv"}],"container-title":["Seminars in Thrombosis and Hemostasis"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.thieme-connect.de\/products\/ejournals\/pdf\/10.1055\/s-0044-1787841.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,1,21]],"date-time":"2025-01-21T23:38:22Z","timestamp":1737502702000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.thieme-connect.de\/DOI\/DOI?10.1055\/s-0044-1787841"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,7,1]]},"references-count":47,"journal-issue":{"issue":"01","published-online":{"date-parts":[[2025,1,21]]},"published-print":{"date-parts":[[2025,2]]}},"URL":"https:\/\/doi.org\/10.1055\/s-0044-1787841","archive":["Portico","CLOCKSS"],"relation":{},"ISSN":["0094-6176","1098-9064"],"issn-type":[{"value":"0094-6176","type":"print"},{"value":"1098-9064","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,7,1]]}}}